This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Econs, M. J. Articles by McEnery, P. T. Search for Related Content PubMed PubMed Citation Articles by Econs, M. J. Articles by McEnery, P. T. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Medline Plus Health Information Rickets

Autosomal Dominant Hypophosphatemic Rickets/Osteomalacia: Clinical Characterization of a Novel Renal Phosphate-Wasting Disorder

Department of Medicine, Duke University Medical Center (M.J.E.), Durham, North Carolina 27710; and the Department of Pediatrics, University of Cincinnati Medical Center and Cincinnati Children’s Hospital (P.T.M.), Cincinnati, Ohio 45229

Address all correspondence and requests for reprints to: Michael J. Econs, M.D., Box 3298, Duke University Medical Center, Durham, North Carolina 27710. E-mail: Econs001{at}mc.duke.edu

Renal phosphate-wasting disorders are the most common form of hereditary rickets and osteomalacia in western countries. Although autosomal dominant transmission of renal phosphate wasting has been described, previous studies included too few affected individuals to adequately characterize the disorder. We performed clinical and biochemical evaluations of individuals from a large kindred with autosomal dominant hypophosphatemic rickets/osteomalacia. We identified 23 affected members in this family, and for some individuals, follow-up was up to 25 yr. As patients were all members of the same kindred, we had the opportunity to determine the clinical manifestations of the disorder in patients who presumably all have the same genetic mutation.

Affected individuals have isolated renal phosphate wasting and inappropriately normal serum calcitriol concentrations. The inheritance pattern was consistent with autosomal dominant transmission with variable penetrance. The family contained two subgroups of affected individuals. Group 1 consisted of patients who presented with renal phosphate wasting as adolescents or adults. These patients presented with bone pain, weakness, and insufficiency fractures, but did not manifest lower extremity deformity. Group 2 consisted of patients who presented with phosphate wasting, rickets, and lower extremity deformity as children. Surprisingly, some individuals in group 2 lost the renal phosphate-wasting defect after puberty.

In conclusion, autosomal dominant hypophosphatemic rickets/osteomalacia is an inherited disorder of isolated renal phosphate wasting. The spectrum of disease includes delayed onset of penetrance and loss of the renal phosphate-wasting defect. Our results have implications in the evaluation of patients who present with renal phosphate wasting as either adults or children.

This article has been cited by other articles:

				H. J. Garringer, M. Malekpour, F. Esteghamat, S. M. J. Mortazavi, S. I. Davis, E. G. Farrow, X. Yu, D. E. Arking, H. C. Dietz, and K. E. White Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E929 - E937. [Abstract] [Full Text] [PDF]

				H. J. Garringer, C. Fisher, T. E. Larsson, S. I. Davis, D. L. Koller, M. J. Cullen, M. S. Draman, N. Conlon, A. Jain, N. S. Fedarko, et al. The Role of Mutant UDP-N-Acetyl-{alpha}-D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4037 - 4042. [Abstract] [Full Text] [PDF]

				D. M. Antoniucci, T. Yamashita, and A. A. Portale Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3144 - 3149. [Abstract] [Full Text] [PDF]

				K. E. White, T. E. Larsson, and M. J. Econs The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23 Endocr. Rev., May 1, 2006; 27(3): 221 - 241. [Abstract] [Full Text] [PDF]

				K. Goji, K. Ozaki, A. H. Sadewa, H. Nishio, and M. Matsuo Somatic and Germline Mosaicism for a Mutation of the PHEX Gene Can Lead to Genetic Transmission of X-Linked Hypophosphatemic Rickets That Mimics an Autosomal Dominant Trait J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 365 - 370. [Abstract] [Full Text] [PDF]

				T. Larsson, S. I. Davis, H. J. Garringer, S. D. Mooney, M. S. Draman, M. J. Cullen, and K. E. White Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed Endocrinology, September 1, 2005; 146(9): 3883 - 3891. [Abstract] [Full Text] [PDF]

				E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]

				T. Berndt and R. Kumar The Phosphatonins and the Regulation of Phosphorus Homeostasis IBMS BoneKEy, June 1, 2005; 2(6): 5 - 16. [Full Text] [PDF]

				T. Larsson, X. Yu, S. I. Davis, M. S. Draman, S. D. Mooney, M. J. Cullen, and K. E. White A Novel Recessive Mutation in Fibroblast Growth Factor-23 Causes Familial Tumoral Calcinosis J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2424 - 2427. [Abstract] [Full Text] [PDF]

				X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders Endocrinology, November 1, 2004; 145(11): 5269 - 5279. [Abstract] [Full Text] [PDF]

				A. E. Nelson, R. C. Bligh, M. Mirams, A. Gill, A. Au, A. Clarkson, H. Juppner, S. Ruff, P. Stalley, R. A. Scolyer, et al. Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4088 - 4094. [Abstract] [Full Text] [PDF]

				N. Azam, M. Y. H. Zhang, X. Wang, H. S. Tenenhouse, and A. A. Portale Disordered Regulation of Renal 25-Hydroxyvitamin D-1{alpha}-Hydroxylase Gene Expression by Phosphorus in X-Linked Hypophosphatemic (Hyp) Mice Endocrinology, August 1, 2003; 144(8): 3463 - 3468. [Abstract] [Full Text] [PDF]

				J Singh, N Moghal, S H S Pearce, and T Cheetham The investigation of hypocalcaemia and rickets Arch. Dis. Child., May 1, 2003; 88(5): 403 - 407. [Abstract] [Full Text] [PDF]

				X.-Y. Bai, D. Miao, D. Goltzman, and A. C. Karaplis The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency J. Biol. Chem., March 7, 2003; 278(11): 9843 - 9849. [Abstract] [Full Text] [PDF]

				H. Saito, K. Kusano, M. Kinosaki, H. Ito, M. Hirata, H. Segawa, K.-i. Miyamoto, and N. Fukushima Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1alpha ,25-Dihydroxyvitamin D3 Production J. Biol. Chem., January 17, 2003; 278(4): 2206 - 2211. [Abstract] [Full Text] [PDF]

				C. Silve and L. Beck Is FGF23 the long sought after phosphaturic factor phosphatonin? Nephrol. Dial. Transplant., June 1, 2002; 17(6): 958 - 961. [Full Text] [PDF]

				S. M. Jan De Beur and M. A. Levine Molecular Pathogenesis of Hypophosphatemic Rickets J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2467 - 2473. [Full Text] [PDF]

				V. M. Brandenburg, M. Ketteler, R. D. Frank, H. Schmitt, J. Floege, C. M. Behler, and J. Riehl Bone pain with scintigraphy suggestive of widespread metastases--do not forget phosphate Nephrol. Dial. Transplant., March 1, 2002; 17(3): 504 - 507. [Full Text] [PDF]

				K. E. White, S. G. Waguespack, M. J. Econs, and R. M. Terek Case 29-2001: Oncogenic Hypophosphatemic Osteomalacia N. Engl. J. Med., January 31, 2002; 346(5): 381 - 382. [Full Text] [PDF]

				P. T. Christie, B. Harding, M. A. Nesbit, M. P. Whyte, and R. V. Thakker X-Linked Hypophosphatemia Attributable to Pseudoexons of the PHEX Gene J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3840 - 3844. [Abstract] [Full Text] [PDF]

				I. A. Holm, A. E. Nelson, B. G. Robinson, R. S. Mason, D. J. Marsh, C. T. Cowell, and T. O. Carpenter Mutational Analysis and Genotype-Phenotype Correlation of the PHEX Gene in X-Linked Hypophosphatemic Rickets J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3889 - 3899. [Abstract] [Full Text] [PDF]

				P. H. Dixon, P. T. Christie, C. Wooding, D. Trump, M. Grieff, I. Holm, J. M. Gertner, J. Schmidtke, B. Shah, N. Shaw, et al. Mutational Analysis of PHEX Gene in X-Linked Hypophosphatemia J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3615 - 3623. [Abstract] [Full Text]

				F. Francis, T. M. Strom, S. Hennig, A. Boddrich, B. Lorenz, O. Brandau, K. L. Mohnike, M. Cagnoli, C. Steffens, S. Klages, et al. Genomic Organization of the Human PEX Gene Mutated in X-Linked Dominant Hypophosphatemic Rickets Genome Res., June 1, 1997; 7(6): 573 - 585. [Abstract] [Full Text] [PDF]